Benzinga | Jul 26, 2021 06:10AM EDT

Genetron Holdings Announces Its AYVAKIT Has Entered Priority Review And Approval Process In China

Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), today announced that its AYVAKIT(r) (avapritinib) companion diagnostic (CDx) kit, developed in partnership with CStone Pharmaceuticals ("CStone", HKEX: 2616) has entered the priority review and approval process under the National Medical Products Administration (NMPA) in China.